Johnson & JohnsonvsPTC Therapeutics

JNJ and PTCT stock compared: price, dividend, valuation and results, from SEC filings.

PTCT

PTC Therapeutics, Inc.

$60.23

Value $5.0B

-0.22%
PTCT's page

Johnson & Johnson (JNJ) has a market value of $657B and PTC Therapeutics (PTCT) $5.0B. Over the last year, with dividends, JNJ moved +39.7% and PTCT -20.3%. Dividend yield: JNJ 1.94%, PTCT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    PTCT$5.0B

    JNJ is 132 times PTCT

  • Revenue, 12 months

    JNJ$99.3B

    PTCT$1.2B

    JNJ is 86 times PTCT

  • Net income, 12 months

    JNJ$16.1B

    PTCT-$106M

  • Operating margin

    JNJ–

    PTCT12.8%

  • ROIC

    JNJ12.4%

    PTCT27.8%

    15.4 points apart

  • P/E

    JNJ40.8

    PTCT–

  • Dividend yield

    JNJ1.9%

    PTCT0.0%

    1.9 points apart

  • 5-year return

    JNJ+92.0%

    PTCT+50.2%

    41.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+92.0%

PTCT+50.2%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsPTCTWith dividends
1 year since November 17, 2025+39.7%Price +36.6%-20.3%Price -20.3%
3 years since November 17, 2023+98.2%+25.6% a yearPrice +82.1%+194.4%+43.3% a yearPrice +194.4%
5 years since November 17, 2021+92.0%+13.9% a yearPrice +67.0%+50.2%+8.5% a yearPrice +50.2%
10 years since November 18, 2016+208.0%+11.9% a yearPrice +136.4%+378.4%+16.9% a yearPrice +378.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPTCTPTC Therapeutics

Valuation

JNJPTCT
Valuation
Price$272.70$60.23
Market value$657B$5.0B
Enterprise value (EV)$685B$3.4B
P/E40.8–
P/E, 5-year median21.9–
P/B8.1–
EV/EBIT38.623.0
Free cash flow yield3.1%0.0%

Results and growth

JNJPTCT
Results and growth
Revenue, 12 months$99.3B$1.2B
Net income, 12 months$16.1B-$106M
Free cash flow, 12 months$20.6B$2.1M
Earnings per share, 12 months$6.59-$1.40
Revenue growth, year on year6.1%114.5%
Revenue growth a year, past+2.7%over 5 years+35.4%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJPTCT
Margins and returns on capital
Gross margin67.6%–
Operating margin–12.8%
Net margin16.2%-9.2%
ROIC12.4%27.8%
ROE19.7%–

Balance sheet

JNJPTCT
Balance sheet
Cash$17.2B$2.1B
Total debt$44.7B$636M
Net debt / EBITDA1.1-8.5
Interest cover18.0×–

Dividends and buybacks

JNJPTCT
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PTCT

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or PTC Therapeutics?

By market value, Johnson & Johnson ($657B) is about 131.8 times PTC Therapeutics ($5.0B), at today's prices.

How did JNJ and PTCT stock do over the last 10 years?

Since November 18, 2016, JNJ's price moved +136.4% and PTCT's +378.4%. With dividends: JNJ +208.0% (+11.9% a year), PTCT +378.4% (+16.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PTCT?

The dividend yield at today's price is 1.94% for Johnson & Johnson and none for PTC Therapeutics. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or PTC Therapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -9.2% for PTC Therapeutics, and the operating margin – and 12.8%. Revenue was $99.3B and $1.2B.

Which is the better investment, Johnson & Johnson or PTC Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.